Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes
Stroke 40:1405-1409, Amarenco,P.,et al, 2009
Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90056 Participants in 14 Randomised Trials of Statins
Lancet 366:1267-1278, Cholesterol Treatment Trialists (CTT) Collaborators, 2005
Cholesterol and Strokes
BMJ 320:459-460, Oliver,M.F., 2000
Effect of HMGcoA Reductase Inhibitors on Stroke, A Meta-Analysis of Controlled Trials
Ann Int Med 128:89-95, Bucher,H.C.,et al, 1998
High-Density Lipoprotein Cholesterol & Risk of Ischemic Stroke Mortality:21-Yr FU of 8586 Men-Israeli Ischemic Heart Dis Study
Stroke 28:83-87, Tanne,D.,et al, 1997
Influence of Cholesterol on Survival After Stroke:Retrospective Study
BMJ 314:1584-1588, Dyker,A.G.,et al, 1997
Epidemiology of Stroke
JNNP 61:333-338, Khaw,K.T., 1996
Cholesterol Reduction and the Risk for Stroke in Men, A Meta-Analysis of Randomized, Controlled Trials
Ann Int Med 119:136-145, Atkins,D.,et al, 1993
Ticlopidine for Prevention of Stroke
The Medical Letter, 34:65-661992., , 1992
Serum Cholesterol Levels & Six-Year Mortality from Stroke in 350, 977 Men Screened for Multiple Risk Factor Interven Trial
NEJM 320:904-910, Iso,H.,et al, 1989
Plasma Cholesterol Concentration and Primary Brain Tumors
BMJ 299:26-27, Davey,G.,et al, 1989